Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS) - Full Text View

Sponsored by:	National Multiple Sclerosis Society
Information provided by:	National Multiple Sclerosis Society
ClinicalTrials.gov Identifier:	NCT00695084

Purpose

This trial will evaluate whether progressive multiple sclerosis associated with hemiparesis may benefit from Constraint-Induced Movement Therapy.

Condition	Intervention	Phase
Multiple Sclerosis	Behavioral: Constraint-Induced Movement Therapy	Phase I

MedlinePlus related topics: Multiple Sclerosis

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Single Group Assignment, Efficacy Study
Official Title:	Constraint-Induced Movement Therapy Trial for Progressive Multiple Sclerosis

Further study details as provided by National Multiple Sclerosis Society:

Primary Outcome Measures:

Improvement on the Motor Activity Log [ Time Frame: One year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Improvement on the Wolf Motor Function Test [ Time Frame: Pre to post-treatment ] [ Designated as safety issue: No ]

Enrollment:	7
Study Start Date:	March 2007
Study Completion Date:	April 2008
Primary Completion Date:	April 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Treatment with Constraint-Induced Movement Therapy	Behavioral: Constraint-Induced Movement Therapy Intensive practice with the hemiparetic arm for 30 contact hours

Detailed Description:

Constraint-Induced Movement Therapy was developed to treat stroke hemiparesis. Due to the similarity between multiple sclerosis and stroke in terms of chronic motor deficit, this trial will attempt to determine whether multiple sclerosis may benefit similarly from Constraint-Induced Movement Therapy.

Eligibility

Ages Eligible for Study:	21 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Chronic upper extremity motor deficit due to multiple sclerosis

Exclusion Criteria:

Relapse within 3 months of planned enrollment.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00695084

Locations

United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35249

Sponsors and Collaborators

National Multiple Sclerosis Society

Investigators

Principal Investigator:

Victor W Mark, MD

University of Alabama at Birmingham

More Information

Responsible Party:	National Multiple Sclerosis Society ( Patricia O'Looney )
Study ID Numbers:	CIMSTrial, PP1395
Study First Received:	June 9, 2008
Last Updated:	June 10, 2008
ClinicalTrials.gov Identifier:	NCT00695084
Health Authority:	United States: Institutional Review Board

Keywords provided by National Multiple Sclerosis Society:

multiple sclerosis

Study placed in the following topic categories:

Autoimmune Diseases
Multiple Sclerosis
Demyelinating Diseases
Demyelinating Autoimmune Diseases, CNS

Demyelinating diseases
Sclerosis
Autoimmune Diseases of the Nervous System

Additional relevant MeSH terms:

Pathologic Processes
Immune System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009